Angiotensin-converting enzyme inhibitors: past, present, and bright future.
Edwards
C R
CR
Padfield
P L
PL
D000804:Angiotensin II / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002216:Captopril / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004151:Dipeptides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000209:etiology; D004347:Drug Interactions; D004656:Enalapril; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy; D006977:Hypertension, Renal / Q000188:drug therapy; D007674:Kidney Diseases / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D011392:Proline / Q000031:analogs & derivatives*; D013651:Taste Disorders / Q000139:chemically induced
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004151:Dipeptides; D000804:Angiotensin II; D004656:Enalapril; D011392:Proline; D002216:Captopril